S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
What to watch for as China's major political meeting of the year gets underway
NYSE:GMED

Globus Medical (GMED) Stock Price, News & Analysis

$54.45
+0.46 (+0.85%)
(As of 03/1/2024 ET)
Today's Range
$53.19
$54.75
50-Day Range
$51.84
$56.52
52-Week Range
$43.38
$62.88
Volume
631,628 shs
Average Volume
1.07 million shs
Market Capitalization
$7.37 billion
P/E Ratio
46.54
Dividend Yield
N/A
Price Target
$67.13

Globus Medical MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.63 Rating Score
Upside/​Downside
23.3% Upside
$67.13 Price Target
Short Interest
Bearish
4.27% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
1.12mentions of Globus Medical in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
22.85%
From $2.67 to $3.28 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.61 out of 5 stars

Medical Sector

89th out of 950 stocks

Surgical & Medical Instruments Industry

14th out of 97 stocks


GMED stock logo

About Globus Medical Stock (NYSE:GMED)

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

GMED Stock Price History

GMED Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Globus Medical price target raised by $3 at Stifel, here's why
Globus Medical: Q4 Earnings Insights
Globus Medical Reports Fourth Quarter and Full Year 2023 Results
PRCT Mar 2024 60.000 call
Globus Medical Q4 2023 Earnings Preview
See More Headlines
Receive GMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Globus Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/20/2024
Today
3/03/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
CUSIP
37957720
Employees
5,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$67.13
High Stock Price Target
$86.00
Low Stock Price Target
$53.00
Potential Upside/Downside
+23.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
8 Analysts

Profitability

Net Income
$122.87 million
Pretax Margin
10.55%

Debt

Sales & Book Value

Annual Sales
$1.02 billion
Cash Flow
$3.61 per share
Book Value
$29.53 per share

Miscellaneous

Free Float
102,477,000
Market Cap
$7.37 billion
Optionable
Optionable
Beta
1.09
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report














GMED Stock Analysis - Frequently Asked Questions

Should I buy or sell Globus Medical stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GMED shares.
View GMED analyst ratings
or view top-rated stocks.

What is Globus Medical's stock price target for 2024?

8 analysts have issued twelve-month price targets for Globus Medical's stock. Their GMED share price targets range from $53.00 to $86.00. On average, they anticipate the company's share price to reach $67.13 in the next year. This suggests a possible upside of 23.3% from the stock's current price.
View analysts price targets for GMED
or view top-rated stocks among Wall Street analysts.

How have GMED shares performed in 2024?

Globus Medical's stock was trading at $53.29 at the beginning of the year. Since then, GMED stock has increased by 2.2% and is now trading at $54.45.
View the best growth stocks for 2024 here
.

Are investors shorting Globus Medical?

Globus Medical saw a increase in short interest in February. As of February 15th, there was short interest totaling 5,780,000 shares, an increase of 8.6% from the January 31st total of 5,320,000 shares. Based on an average trading volume of 1,220,000 shares, the short-interest ratio is presently 4.7 days.
View Globus Medical's Short Interest
.

When is Globus Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our GMED earnings forecast
.

How were Globus Medical's earnings last quarter?

Globus Medical, Inc. (NYSE:GMED) issued its earnings results on Tuesday, February, 20th. The medical device company reported $0.60 earnings per share for the quarter, beating analysts' consensus estimates of $0.59 by $0.01. The medical device company earned $616.53 million during the quarter, compared to the consensus estimate of $608.21 million. Globus Medical had a trailing twelve-month return on equity of 8.82% and a net margin of 7.83%. The company's revenue was up 124.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.59 EPS.

What guidance has Globus Medical issued on next quarter's earnings?

Globus Medical issued an update on its FY 2024 earnings guidance on Tuesday, February, 20th. The company provided earnings per share (EPS) guidance of 2.680-2.700 for the period, compared to the consensus estimate of 2.690. The company issued revenue guidance of $2.5 billion-$2.5 billion, compared to the consensus revenue estimate of $2.5 billion.

What is David Demski's approval rating as Globus Medical's CEO?

47 employees have rated Globus Medical Chief Executive Officer David Demski on Glassdoor.com. David Demski has an approval rating of 61% among the company's employees. This puts David Demski in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Globus Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Globus Medical investors own include NVIDIA (NVDA), Shopify (SHOP), CrowdStrike (CRWD), Okta (OKTA), Trade Desk (TTD), Block (SQ), Tesla (TSLA), Teladoc Health (TDOC), Zoom Video Communications (ZM) and Mastercard (MA).

Who are Globus Medical's major shareholders?

Globus Medical's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.18%), Dimensional Fund Advisors LP (1.32%), Norges Bank (1.30%), GW&K Investment Management LLC (1.28%), Burgundy Asset Management Ltd. (1.23%) and Geneva Capital Management LLC (1.03%). Insiders that own company stock include Dan Lemaitre, Daniel T Scavilla, Daniel T Scavilla, David D Davidar, David M Demski, James R Tobin, James R Tobin, Keith W Pfeil, Keith W Pfeil and Kelly Huller.
View institutional ownership trends
.

How do I buy shares of Globus Medical?

Shares of GMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:GMED) was last updated on 3/3/2024 by MarketBeat.com Staff